Diabetes Mellitus Impacts on COVID-19 Outcomes

Diabetes mellitus has emerged as one of the most significant comorbidities influencing the course and prognosis of COVID-19. People living with diabetes exhibit a heightened susceptibility to severe manifestations of SARS-CoV-2 infection, including acute respiratory distress syndrome, systemic inflammation and coagulopathy. Chronic hyperglycaemia fosters endothelial dysfunction, impairs innate and adaptive immune responses, and promotes a pro-inflammatory milieu characterised by elevated cytokine levels. These alterations contribute to a more aggressive disease trajectory, marked by prolonged hospital stays, increased need for mechanical ventilation and higher mortality rates. Glycaemic control prior to and during SARS-CoV-2 infection appears to be a critical determinant of outcome: tighter blood glucose management correlates with fewer complications and reduced risk of “cytokine storm.” Beyond metabolic control, the interplay between antidiabetic therapies and COVID-19 outcomes has drawn considerable attention, leading to trials exploring repurposed agents. Globally, the burden of diabetes amplifies health-care demands during pandemic surges, underlining the imperative for integrated strategies that combine vigilant monitoring, optimisation of treatment regimens and rapid adjustment of therapies in the event of SARS-CoV-2 infection. Effective management of diabetes in the context of COVID-19 requires multidisciplinary coordination to mitigate acute risks and long-term sequelae.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Diabetes Mellitus Impacts on COVID-19 Outcomes publication trend

The graph below shows the total number of articles in diabetes mellitus impacts on covid-19 outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Diabetes Mellitus: A chronic metabolic disorder characterised by elevated blood glucose due to insufficient insulin secretion or action.

Hyperglycaemia: An abnormal rise in blood glucose levels, often assessed by fasting blood glucose or glycated haemoglobin (HbA1c).

SGLT2 inhibitor: A class of glucose-lowering drugs that inhibit renal sodium–glucose cotransporter 2, promoting urinary excretion of glucose.

Alpha-glucosidase inhibitor: An oral antidiabetic agent that delays carbohydrate absorption in the small intestine to reduce postprandial glycaemic spikes.

Meta-analysis: A quantitative technique that combines and synthesises data from multiple independent studies to produce pooled estimates of effect size.

References

1. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology (2023).
2. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis. Diabetologia (2023).
3. Effects of different treatments for type 2 diabetes mellitus on mortality of coronavirus disease from 2019 to 2021 in China: a multi-institutional retrospective study. Molecular Biomedicine (2024).